Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L21 pseudogene 80 (RPL21P80) is a processed pseudogene—a DNA segment with high sequence similarity to the ribosomal protein L21 gene (RPL21)—but does not code for a functional protein product[2]. Pseudogenes arise from duplication or retrotransposition events and are generally non-functional, lacking the regulatory elements or sequences necessary for protein expression. There is no evidence that RPL21P80 is transcribed or translated, nor is it associated with therapeutic targeting or disease relevance. The functional gene RPL21 encodes a protein component of the ribosomal large 60S subunit with roles in protein synthesis and, in some contexts, cell growth and disease, but this does not extend to its pseudogenes[1][3][5][2]. "Ribosomal protein L21 pseudogene 80" is not a drug target and has no established biological role, disease association, or pharmacological relevance. If focused on a protein-coding gene with therapeutic or biological significance, refer to the *RPL21* gene/protein, not its pseudogene[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 80 (RPL21P80).